

INTERNATIONAL DRUG AGENCY FOR PHARMACEUTICAL INDUSTRY (IDI) - 542648

PAGE NO. : 1

MIRA INFORM REPORT

Report No. :	542648
Report Date :	06.12.2018

IDENTIFICATION DETAILS

Name :	INTERNATIONAL DRUG AGENCY FOR PHARMACEUTICAL INDUSTRY (IDI)
Registered Office :	Saudia Buildings 4, El Nozha Street, Heliopolis, Cairo Governorate, Nasr City
Country :	Egypt
Financials (as on) :	31.12.2017 (Summarized)
Date of Incorporation :	21.03.2000
Com. Reg. No.:	3753
Legal Form :	Joint Stock Company
Line of Business :	Manufacturers and distributors of pharmaceutical products.
No. of Employees :	250

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January 2017)

MIRA's Rating :	B
------------------------	---

Credit Rating	Explanation	Rating Comments
B	Medium Risk	Business dealings permissible on a regular monitoring basis

Status :	Moderate
Payment Behaviour :	Slow but Correct
Litigation :	Clear

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.



MIRA INFORM PRIVATE LIMITED
605, Palmspring, Near D'Mart, Link Road,
Malad (West), Mumbai - 400 064. INDIA
Tel : 91-22-40448000 (44 lines)
Fax : 91-22-40448045 / 40448046
E-mail : mira@mirainform.com
info@mirainform.com
Website : <http://www.mirainform.com>
<http://www.miraglobalcheck.com>
<http://www.miraglobalcollections.com>

INTERNATIONAL DRUG AGENCY FOR PHARMACEUTICAL INDUSTRY (IDI) - 542648

PAGE NO. : 2

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

INTERNATIONAL DRUG AGENCY FOR PHARMACEUTICAL INDUSTRY (IDI) - 542648

PAGE NO. : 3

SUMMARY

COMPANY NAME INTERNATIONAL DRUG AGENCY FOR PHARMACEUTICAL INDUSTRY (IDI)

ADDRESS Building Street Area Town
Saudia El Nozha Street Heliopolis, Cairo Nasr City
Buildings 4 Governorate

TEL/FAX Verified Phones: (+20 2) 2418 4269 / Fax: (+20 2) 2291 4898

EMAIL/WEBSITE Email: idipharma@gmail.com / idi_pharm@hotmail.com Website: www.idipharma.com

ACTIVITY NACE 4646 - Wholesale of pharmaceutical goods;

PRINCIPAL Hussein Hassanein Hassan Workforce
Chairman 250

LEGAL INFO Date Of Est. Reg. No. Legal Form Status
21/03/2000 3753 Joint Stock Company Active

IDENTIFICATION

CO. NAME INTERNATIONAL DRUG AGENCY FOR PHARMACEUTICAL INDUSTRY (IDI)

ALSO KNOWN NAME (S) IDI

BUILDING Saudia Buildings 4

STREET El Nozha Street

AREA Heliopolis, Cairo Governorate

TOWN Nasr City

COUNTRY Egypt

TELEPHONE (+20 2) 2418 4269 / (+20 2) 2291 4898 / (+20 10) 6667 9624

FAX (+20 2) 2291 4898

VERIFIED EMAIL idipharma@gmail.com / idi_pharm@hotmail.com

WEBSITE www.idipharma.com

BUSINESS HOURS **DAYS** **OFFICE HOURS** **BREAK TIME**
Sun-Thu 08:00-18:00 13:00-14:00

FACTORY ADDRESS 2nd Industrial Zone
East Port Said
Western Port of the Part No. Slide (A)
Port Said.
Egypt

SENIOR PERSONNEL

MANAGEMENT	NAME	POSITION
	Dr. Hussein Hassanein Hassan	Chairman
	Hasan Hassanein Hassan	Managing Director
	Farid El Khatib	Finance Manager
	Dr. Ahmad Hosmi	Quality Assurance Manager
	Mohammed Khatab	HR Manager
	Ms. Mona Momen	Secretary
WORKFORCE	NO. OF EMPLOYEES	PERIOD
	250	12.2018

FINANCIAL SUMMARY

TURNOVER	31/12/2017	31/12/2016
	EGP 23,000,000	EGP 16,000,000
(LOSS)	Not given but stated to be in loss situation	
TURNOVER (PROJECTED)	EGP 30,000,000 – 2018	
STOCK/INVENTORIES	EGP 7,000,000 as of December 2018	
FIXED ASSETS	EGP 60,000,000 as of December 2018	
FISCAL YEAR-END	31 December.	

LEGAL STATUS

INCORPORATION	21/03/2000	
REGISTRATION NO.	3753	
CAPITAL	Not provided	
BUSINESS HISTORY	The Company was incorporated in Egypt on 21 March 2000 and commenced production in 2009.	
LEGAL FORM	Joint Stock Company	
STATUS	Active	
SHAREHOLDERS	NAME	PERCENTAGE
	1. Dr. Hussein Hassanein Hassan	00.00%
	Nationality: Egyptian	

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

2. Hasan Hassanein Hassan
Nationality: Egyptian
3. Abdullah Mohammed Nasser
Nationality: Egyptian
4. Khaled Musaed Behiry
Nationality: Egyptian
5. Mohammed Kamal Samaha
Nationality: Egyptian

* The exact shareholding percentage was not disclosed.

OPERATION

BANKERS

1. Qatar National Bank Al Ahli
380, Jawharet El-Maadi Tower, Corniche El-Nile, 11431, Maadi
Cairo
Egypt
Phone: (+20 2) 2529 6400
Fax : (+20 2) 2529 6499
2. National Bank of Egypt
NBE Tower, 1187 Corniche El Nil St., Boulak,
Cairo
Egypt
Phone: (+20 2) 2594 5000
Fax : (+20 2) 2594 5137

ACTIVITY CODE (NACE) LINE OF BUSINESS

4646 - Wholesale of pharmaceutical goods;
Manufacturers and distributors of pharmaceutical products.

Subject offers a wide range of vitamin supplements which includes b12 as well as antihypertensive agents which includes caprol.

IMPORT FROM EXPORT TO FACILITIES

Subject holds ISO 9001/2008 certification.
mainly from Europe.

Subject currently does not export, all sales are domestic.
Premises comprising administrative offices located at the heading address as well as a factory located in 2nd Industrial Zone, East Port Said, Western Port of the Part No. Slide (A), Port Said, Egypt.

INTERNATIONAL DRUG AGENCY FOR PHARMACEUTICAL INDUSTRY (IDI) - 542648

PAGE NO. : 6

RELATED COMPANIES

Associates

1. International Drug Agency Company
Egypt
2. Sina Pharm Company
Egypt
3. Gal Pharm Company
Egypt

PAYMENT

CREDIT OPINION

We consider it is acceptable to deal with subject with some caution

SPECIAL REMARKS

INTERVIEWED

Farid El Khatib (Finance Manager) and Dr. Ahmad Hosmi (Quality Assurance Manager).

INTERNATIONAL DRUG AGENCY FOR PHARMACEUTICAL INDUSTRY (IDI) - 542648

PAGE NO. : 7

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	INR 70.35
UK Pound	1	INR 89.65
Euro	1	INR 80.08
EGP	1	INR 3.96

Note : Above are approximate rates obtained from sources believed to be correct

INFORMATION DETAILS

Analysis Done by :	VIV
Report Prepared by :	TRU

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

RATING EXPLANATIONS

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC's credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

- Financial condition covering various ratios
- Company background and operations size
- Promoters / Management background
- Payment record
- Litigation against the subject
- Industry scenario / competitor analysis
- Supplier / Customer / Banker review (wherever available)